Atlas Trials

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Clinical trial NCT05846763 · RECRUITING

Trial details

NCT number
NCT05846763
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Study type
OBSERVATIONAL
Follicular Lymphoma
Start date
2022-11-01
Primary completion
2026-05-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.